Before making a mammoth, ask the public
By Victoria Herridge,
Nature
| 10. 20. 2021
Image by Russ Seidel on Flickr
Every few years for the past 20 or so, the story resurfaces, frozen in time like a permafrost carcass. At some future point, typically within the decade, scientists hope to ‘bring back the mammoth’. There have been a few tantalizing results — stirrings in mammoth nuclei transplanted into mouse eggs (K. Yamagata et al. Sci. Rep. 9, 4050; 2019) — but that’s it. Hence raised eyebrows at last month’s announcement by de-extinction champion and geneticist George Church, co-founder (with entrepreneur Ben Lamm) of biotechnology start-up Colossal: yet again, the world has about five years until a wobbly, woolly calf takes its first steps into the Anthropocene.
What Colossal actually aims to produce is less a mammoth than a new synthetic species, a chimaera of Asian elephant DNA and mitochondria, mammoth genetic code and, from the probable surrogate dam, African elephant epigenetics. The resulting cold-adapted elephants — Colossal hopes — will trample and graze northern Siberia to create something akin to the Ice Age grasslands of the woolly mammoth’s heyday. Compacted...
Related Articles
By Isaac Schultz, Gizmodo | 10.18.2024
Colossal Biosciences, a company mainly known for intending to genetically engineer proxies for several iconic extinct species, announced this week that it has made major steps towards the de-extinction of the thylacine, or Tasmanian tiger.
The thylacine was a carnivorous...
By Russ Burlingame, Comicbook | 07.23.2024
Colossal Laboratories and Biosciences, a biotech company that's putting together plans to orchestrate the de-extinction for animals like the dodo and the wooly mammoth, made some waves on Reddit recently when they petitioned the United Federation of Planets -- the...
By Shelly Fan, Singularity Hub | 05.31.2024
We all know the drill for reproduction—sperm meets egg.
For the past decade, scientists have been pushing the boundaries of where the two halves come from. Thanks to induced pluripotent stem cell technology, it’s now possible to scrape skin cells...
By Alison Snyder, Axios | 06.06.2024
Gene editing's next chapter will be focused on tackling cancers and more common diseases, uncovering new details about aging and other fundamental aspects of biology and editing RNA, top scientists in the field said this week.
The big picture: ...